#TB2016    



TB2016 Presentations - Saturday 16 July 2016 (Session Room 12)


Plenary Session

Understanding the biology of tuberculosis and its impact on drug discovery and development
Clifton Barry, National Institute of Allergy and Infectious Diseases

Critical questions and new approaches in TB vaccinology
Willem Hanekom, Bill & Melinda Gates Foundation

How latent is latent TB?
Robert Wilkinson, Crick Institute and University of Cape Town

Using rights to health and scientific progress to advance TB research and access
Mike Frick, Treatment Action Group




Breakout Session 1 - New Approaches in Prevention Research

Towards a correlate of protective immunity to TB
David Russell, Cornell University

Potential indications and target populations for a new TB vaccine
Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town

Drivers of tuberculosis transmission
Robin Wood, Desmond Tutu HIV Centre, University of Cape Town

Serial Quantiferon testing predicts disease risk among infants in high-transmission settings
Jason Andrews, Stanford University School of Medicine




Abstract Session 1 - MDR and XDR: diagnosis and impact

Abstract No. O05 Higher cost of implementing Xpert MTB/RIF in peripheral settings in Uganda: Implications for cost-effectiveness
E. Hsiang
Poster

Abstract No. O06 Large-scale expansion of drug resistant tuberculosis case-finding in Mumbai via private provider engagement
R. Chopra
Poster

Abstract No. O07 Development of a reporter mycobacteriophage assay to detect emergent drug resistant MTB subpopulations
L. Uccellini
Poster

Abstract No. O08 Significant and sustained decline in extensively and multiple drug resistant tuberculosis (XDR/MDR TB) from 2005-2014 in Tugela Ferry, KwaZulu-Natal South Africa
G. Friedland
Poster




Breakout Session 3 - Understanding and Intervening in Progression from Infection to Disease

Advantage of rifamycin containing regimens over isoniazid in high transmission settings: What is the evidence?
Tom Sumner, London School of Hygiene & Tropical Medicine

Advances in LTBI regimens: An update on ongoing clinical trials
Tim Sterling, Vanderbilt Tuberculosis Center

Are there lessons for TB from long-acting ART?
Sue Swindells, University of Nebraska Medical Center

Abstract No. O21 High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of TB/HIV co-infected patients: The RAFA trial results
Corinne Simone Merle, WHO




Breakout Session 5 - TB Drug Discovery and Development - Where are we Heading?

Opportunities and challenges in TB drug discovery: Lessons from the benzothiazinones
Stewart Cole, École Polytechnique Fédérale de Lausanne

Lesion penetration as a critical determinant of TB drug efficacy
Rada Savic, University of California, San Francisco

Prospects for antimicrobial drug repurposing
Florian Von Groote-Bidlingmaier, TASK Applied Science

Novel pathways for host-targeted therapy
Jerrold Ellner, Boston University